WEBSITE BSE:0 NSE: Inc. Year: 2004 Industry: Pharmaceuticals & Drugs My Bucket: Add Stock
Last updated: 15:59
No Notes Added Yet
Sakar Healthcare ltd. is an totally India-based organisation, which is engaged within the production of pharmaceutical products. The Company is engaged in presenting Liquid Orals, Cephalosporin Tablet, Capsule, Dry Powder Syrup, Liquid Injectables in ampoules and vials, and Dry Powder Injections. It additionally affords Lyophilized Injectables. It operates as contract manufacturer for pharmaceutical MNC. The Company's products include Albendazole oral suspension USP, Cetirizine hydrochloride syrup, Cefadroxil and potassium clavulanate capsules,...Read More
Sakar Healthcare ltd. is an totally India-based organisation, which is engaged within the production of pharmaceutical products. The Company is engaged in presenting Liquid Orals, Cephalosporin Tablet, Capsule, Dry Powder Syrup, Liquid Injectables in ampoules and vials, and Dry Powder Injections. It additionally affords Lyophilized Injectables. It operates as contract manufacturer for pharmaceutical MNC. The Company's products include Albendazole oral suspension USP, Cetirizine hydrochloride syrup, Cefadroxil and potassium clavulanate capsules, Cefixime and potassium clavulanate capsules, Cefpodoxime proxetil Capsule, Cefalexin oral suspension BP, Cefixime for oral suspension, Cefuroxime Axetil drugs BP, Adrenallin tartrate Injection, Quinine dihydrochloride Injection, Vitamin B-complicated Injection, Chloroquine phosphate Injection, Tranexamic Acid Injection, Palonosetron hydrochloride Injection and others. The Company has its presence in about 40 international locations. ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹1267 Cr.
Stock P/E 72.4
P/B 4
Current Price ₹569.7
Book Value ₹ 140.9
Face Value 10
52W High ₹662
Dividend Yield 0%
52W Low ₹ 305
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 37 | 43 | 41 | 43 | 43 | 50 | 53 | 58 | 70 | 71 |
| Other Income | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| Total Income | 37 | 44 | 42 | 43 | 44 | 50 | 53 | 59 | 71 | 71 |
| Total Expenditure | 28 | 32 | 30 | 31 | 32 | 35 | 40 | 46 | 52 | 45 |
| Operating Profit | 9 | 12 | 11 | 12 | 12 | 16 | 13 | 13 | 19 | 26 |
| Interest | 2 | 2 | 1 | 2 | 1 | 4 | 2 | 2 | 2 | 2 |
| Depreciation | 4 | 5 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 3 | 5 | 5 | 5 | 5 | 6 | 5 | 5 | 11 | 18 |
| Provision for Tax | 1 | 2 | 2 | 0 | 1 | 0 | 1 | 1 | 1 | 7 |
| Profit After Tax | 2 | 3 | 2 | 5 | 5 | 6 | 5 | 5 | 10 | 11 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | -0 | 0 | 0 | -0 | -0 |
| Profit After Adjustments | 2 | 3 | 2 | 5 | 5 | 6 | 5 | 5 | 10 | 11 |
| Adjusted Earnings Per Share | 1 | 1.4 | 1.1 | 2.2 | 2.1 | 2.6 | 2.1 | 2 | 4.6 | 5 |
| #(Fig in Cr.) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Net Sales | 83 | 95 | 128 | 133 | 153 | 178 | 252 |
| Other Income | 2 | 1 | 2 | 5 | 3 | 1 | 2 |
| Total Income | 85 | 96 | 130 | 138 | 157 | 179 | 254 |
| Total Expenditure | 63 | 72 | 99 | 100 | 115 | 128 | 183 |
| Operating Profit | 22 | 24 | 32 | 38 | 42 | 51 | 71 |
| Interest | 2 | 2 | 3 | 6 | 8 | 9 | 8 |
| Depreciation | 7 | 8 | 10 | 15 | 18 | 21 | 24 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | -0 | 0 |
| Profit Before Tax | 12 | 13 | 19 | 17 | 16 | 22 | 39 |
| Provision for Tax | 3 | 3 | 4 | 4 | 4 | 4 | 10 |
| Profit After Tax | 10 | 11 | 15 | 13 | 12 | 18 | 31 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 10 | 11 | 15 | 13 | 12 | 18 | 31 |
| Adjusted Earnings Per Share | 6.4 | 6.8 | 8.9 | 6.7 | 5.4 | 8 | 13.7 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 16% | 12% | 16% | 0% |
| Operating Profit CAGR | 21% | 17% | 18% | 0% |
| PAT CAGR | 50% | 6% | 12% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 87% | 33% | 31% | NA% |
| ROE Average | 6% | 7% | 9% | 10% |
| ROCE Average | 8% | 8% | 10% | 11% |
| #(Fig in Cr.) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Shareholder's Funds | 81 | 98 | 127 | 173 | 262 | 285 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 12 | 38 | 85 | 98 | 55 | 54 |
| Other Non-Current Liabilities | 7 | 8 | 9 | 10 | 12 | 13 |
| Total Current Liabilities | 14 | 33 | 47 | 54 | 59 | 63 |
| Total Liabilities | 115 | 178 | 268 | 336 | 389 | 415 |
| Fixed Assets | 66 | 69 | 205 | 267 | 314 | 309 |
| Other Non-Current Assets | 28 | 75 | 13 | 14 | 3 | 18 |
| Total Current Assets | 22 | 34 | 50 | 56 | 72 | 89 |
| Total Assets | 115 | 178 | 268 | 336 | 389 | 415 |
| #(Fig in Cr.) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash Flow from Operating Activities | 19 | 15 | 36 | 33 | 24 | 34 |
| Cash Flow from Investing Activities | -22 | -47 | -90 | -74 | -52 | -31 |
| Cash Flow from Financing Activities | 3 | 32 | 55 | 41 | 27 | -3 |
| Net Cash Inflow / Outflow | -0 | -0 | -0 | 0 | 0 | -0 |
| Closing Cash & Cash Equivalent | 0 | 0 | 0 | 0 | 0 | 0 |
| # | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 6.43 | 6.84 | 8.87 | 6.7 | 5.37 | 7.97 |
| CEPS(Rs) | 11.16 | 12 | 14.52 | 14.57 | 13.67 | 17.49 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 54.35 | 63.04 | 74.45 | 91.04 | 118.41 | 128.75 |
| Core EBITDA Margin(%) | 23.56 | 23.87 | 22.88 | 24.94 | 25.03 | 27.99 |
| EBIT Margin(%) | 17.46 | 16.6 | 17.03 | 17.21 | 15.33 | 16.94 |
| Pre Tax Margin(%) | 14.73 | 13.97 | 14.76 | 12.74 | 10.37 | 12.12 |
| PAT Margin (%) | 11.6 | 11.28 | 11.84 | 9.57 | 7.61 | 9.86 |
| Cash Profit Margin (%) | 20.13 | 19.78 | 19.38 | 20.8 | 19.38 | 21.61 |
| ROA(%) | 8.36 | 7.3 | 6.81 | 4.22 | 3.22 | 4.35 |
| ROE(%) | 11.83 | 11.88 | 13.44 | 8.48 | 5.42 | 6.48 |
| ROCE(%) | 14.79 | 13.16 | 12.09 | 8.95 | 7.42 | 8.43 |
| Receivable days | 36.22 | 39.7 | 37.8 | 49.62 | 51.16 | 53.06 |
| Inventory Days | 48.09 | 51.3 | 42.53 | 40.48 | 51.33 | 73.3 |
| Payable days | 46.13 | 90.05 | 123.3 | 140.43 | 116.77 | 107.64 |
| PER(x) | 7.77 | 16.54 | 15.24 | 29.94 | 68.64 | 26.55 |
| Price/Book(x) | 0.92 | 1.79 | 1.82 | 2.2 | 3.11 | 1.64 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 1.1 | 2.31 | 2.53 | 3.76 | 5.74 | 3.1 |
| EV/Core EBITDA(x) | 4.22 | 9.21 | 10.29 | 13.21 | 21.17 | 10.8 |
| Net Sales Growth(%) | 0 | 14.17 | 35.35 | 4 | 14.99 | 15.8 |
| EBIT Growth(%) | 0 | 8.57 | 38.88 | 5.09 | 2.45 | 27.92 |
| PAT Growth(%) | 0 | 11.01 | 42.1 | -15.95 | -8.53 | 49.96 |
| EPS Growth(%) | 0 | 6.34 | 29.65 | -24.44 | -19.92 | 48.59 |
| Debt/Equity(x) | 0.2 | 0.43 | 0.73 | 0.69 | 0.31 | 0.31 |
| Current Ratio(x) | 1.52 | 1.01 | 1.07 | 1.03 | 1.21 | 1.4 |
| Quick Ratio(x) | 0.75 | 0.54 | 0.77 | 0.74 | 0.74 | 0.71 |
| Interest Cover(x) | 6.41 | 6.3 | 7.51 | 3.85 | 3.09 | 3.52 |
| Total Debt/Mcap(x) | 0.22 | 0.24 | 0.4 | 0.31 | 0.1 | 0.19 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 53.15 | 53.15 | 53.15 | 53.15 | 53.58 | 53.58 | 52.86 | 52.86 | 52.86 | 52.86 |
| FII | 13.76 | 13.52 | 13.52 | 13.42 | 13.58 | 13.61 | 13.41 | 13.31 | 13.05 | 12.94 |
| DII | 10.62 | 10.62 | 10.62 | 10.62 | 10.88 | 10.97 | 11.25 | 11.43 | 11.36 | 11.32 |
| Public | 22.47 | 22.71 | 22.71 | 22.8 | 21.96 | 21.85 | 22.48 | 22.41 | 22.73 | 22.87 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 1.16 | 1.16 | 1.16 | 1.16 | 1.18 | 1.18 | 1.18 | 1.18 | 1.18 | 1.18 |
| FII | 0.3 | 0.29 | 0.29 | 0.29 | 0.3 | 0.3 | 0.3 | 0.3 | 0.29 | 0.29 |
| DII | 0.23 | 0.23 | 0.23 | 0.23 | 0.24 | 0.24 | 0.25 | 0.25 | 0.25 | 0.25 |
| Public | 0.49 | 0.49 | 0.49 | 0.5 | 0.48 | 0.48 | 0.5 | 0.5 | 0.51 | 0.51 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2.17 | 2.17 | 2.17 | 2.17 | 2.19 | 2.19 | 2.22 | 2.22 | 2.22 | 2.22 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
ChatGPT
Claude
Perplexity
